



# Financial Tear Sheet

Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from GSDIa, phenylketonuria (PKU), Wilson disease, and citrullinemia; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in OTC deficiency, which is in a Phase 1/2 clinical trial. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.


## PRIMARY IR CONTACT

Jean Franchi  
 Chief Financial Officer  
**Phone:** 617-714-0709  
**E-mail:** [ir@dimensiontx.com](mailto:ir@dimensiontx.com)  
 (<mailto:ir@dimensiontx.com>)

## STOCK INFORMATION

### DMTX (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	<b>\$5.90</b>
Change (%)	▲ 0.05 (0.85%)
Volume	108,903
52 Week Low	\$1.05
Market Cap	\$147,810,505
Rolling EPS	-2.13
PE Ratio	0
Shares Outstanding	25,052,628
Data as of 09/22/17 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

## RECENT PRESS RELEASES & EVENTS

September 19, 2017 - 8:01 a.m.

Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a "Superior Proposal"

September 18, 2017 - 3:10 p.m.

Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx

August 31, 2017 - 8:00 a.m.

Dimension Therapeutics Commences Patient Dosing in Global, Multi-Center Phase 1/2 Clinical Trial of DTX301 in Ornithine Transcarbamylase (OTC) Deficiency

There are currently no events scheduled.

## SEC FILINGS

Filing Date	Form
09/19/17	DEFA14A
09/19/17	SC TO-C
09/19/17	8-K
09/19/17	DEFA14A